Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Ch282-5 + Oxaliplatin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Ch282-5||BCL2 Family Inhibitor 6||Ch282-5 is a gossypol derivative that binds to and inhibits BCL2, family proteins, resulting in decreased tumor cell growth and increased sensitivity to chemotherapeutic agents (PMID: 26515494, PMID: 29885833).|
|Oxaliplatin||Eloxatin||Diaminocyclohexane Oxalatoplatinum||Chemotherapy - Platinum 7||Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|